Document is current

Article History

Received: 25 February 2022

Revised: 13 July 2022

Accepted: 19 July 2022

First Online: 19 August 2022

Competing interests

: AT, DC, UW, AM, AB and PN declare no potential conflicts of interest that pertain to this work. CS reports honoraria for advisory boards from Roche, MSD, Bayer, Servier, AstraZeneca and Eisai outside the submitted work. MTD declares speaker and advisory board activities for AstraZeneca, Eisai and Roche outside the submitted work. DK declares personal fees from Agilent, AstraZeneca, Bristol-Myers Squibb, Lilly, Pfizer, and Takeda outside the submitted work. TLu declares research support and/or speaker´s honoraria from AstraZeneca, Bayer, BMS, EASL, Incyte, MSD and Roche. AS declares speakers´ bureau and advisory board activities by AGCT, Aignostics, Amgen, AstraZeneca, Bayer, BMS, Eli Lilly, Illumina, Incyte, Janssen, MSD, Novartis, Pfizer, Roche, Seattle Genetics, Takeda and Thermo Fisher as well as grant support by Bayer, BMS, Chugai, and Incyte. PS declares speakers´ bureau activities for BMS, Incyte, Eisai, Leica, Janssen, Novartis, advisory board activities for AstraZeneca, Bayer, BMS, Eisai, Incyte, MSD and Roche as well as grant support from BMS, Chugai, Incyte, MSD and Roche outside the submitted work. TLo declares the speaker´s honorarium by Incyte.

: The LCCH registry study was approved by the local ethics committee of the Heidelberg University Hospital (S-693/2019). Informed consent was obtained from all prospectively enrolled patients. The study was performed in accordance with the Declaration of Helsinki.

: Not applicable.